A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout
Trial · NCT05007392
Results by group54
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 54
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Serum Uric Acid (SUA) Level <=6.0 mg/dL at Week 24 (LOCF) | Febuxostat | 38.1 | 95% Confidence Interval 31.6 to 44.5 | percentage of participants | |
| Percentage of Participants With Serum Uric Acid (SUA) Level <=6.0 mg/dL at Week 24 (LOCF) | Dotinurad | 73.6 | 95% Confidence Interval 67.8 to 79.5 | percentage of participants | |
| Percentage of Participants With SUA Level <=6.0 mg/dL at Week 12 (LOCF) | Febuxostat | 50.5 | 95% Confidence Interval 43.8 to 57.1 | percentage of participants | |
| Percentage of Participants With SUA Level <=6.0 mg/dL at Week 12 (LOCF) | Dotinurad | 55.5 | 95% Confidence Interval 48.9 to 62.0 | percentage of participants | |
| Percentage of Participants With SUA Level <=6.0 mg/dL at Weeks 4, 8, 12, 16, 20 and 24 | Febuxostat | Week 4 | 26.3 | percentage of participants | |
| Percentage of Participants With SUA Level <=6.0 mg/dL at Weeks 4, 8, 12, 16, 20 and 24 | Dotinurad | Week 4 | 27.6 | percentage of participants | |
| Percentage of Participants With SUA Level <=6.0 mg/dL at Weeks 4, 8, 12, 16, 20 and 24 | Febuxostat | Week 8 | 55.6 | percentage of participants | |
| Percentage of Participants With SUA Level <=6.0 mg/dL at Weeks 4, 8, 12, 16, 20 and 24 | Dotinurad | Week 8 | 62.7 | percentage of participants | |
| Percentage of Participants With SUA Level <=6.0 mg/dL at Weeks 4, 8, 12, 16, 20 and 24 | Febuxostat | Wee 12 | 52.8 | percentage of participants | |
| Percentage of Participants With SUA Level <=6.0 mg/dL at Weeks 4, 8, 12, 16, 20 and 24 | Dotinurad | Wee 12 | 56.9 | percentage of participants | |
| Percentage of Participants With SUA Level <=6.0 mg/dL at Weeks 4, 8, 12, 16, 20 and 24 | Febuxostat | Week 16 | 48.7 | percentage of participants | |
| Percentage of Participants With SUA Level <=6.0 mg/dL at Weeks 4, 8, 12, 16, 20 and 24 | Dotinurad | Week 16 | 84.7 | percentage of participants | |
| Percentage of Participants With SUA Level <=6.0 mg/dL at Weeks 4, 8, 12, 16, 20 and 24 | Febuxostat | Week 20 | 53.7 | percentage of participants | |
| Percentage of Participants With SUA Level <=6.0 mg/dL at Weeks 4, 8, 12, 16, 20 and 24 | Dotinurad | Week 20 | 83.0 | percentage of participants | |
| Percentage of Participants With SUA Level <=6.0 mg/dL at Weeks 4, 8, 12, 16, 20 and 24 | Febuxostat | Week 24 | 40.2 | percentage of participants | |
| Percentage of Participants With SUA Level <=6.0 mg/dL at Weeks 4, 8, 12, 16, 20 and 24 | Dotinurad | Week 24 | 78.1 | percentage of participants | |
| Mean Percent Reduction From Baseline in SUA Level at Weeks 4, 8, 12, 16, 20 and 24 | Febuxostat | Percent Reduction from Baseline at Week 4 | 26.43 | Standard Deviation 13.200 | Percent change in SUA level |
| Mean Percent Reduction From Baseline in SUA Level at Weeks 4, 8, 12, 16, 20 and 24 | Dotinurad | Percent Reduction from Baseline at Week 4 | 27.43 | Standard Deviation 14.754 | Percent change in SUA level |
| Mean Percent Reduction From Baseline in SUA Level at Weeks 4, 8, 12, 16, 20 and 24 | Febuxostat | Percent Reduction from Baseline at Week 8 | 37.06 | Standard Deviation 14.018 | Percent change in SUA level |
| Mean Percent Reduction From Baseline in SUA Level at Weeks 4, 8, 12, 16, 20 and 24 | Dotinurad | Percent Reduction from Baseline at Week 8 | 39.10 | Standard Deviation 18.931 | Percent change in SUA level |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05007392/results